bioRxivCancer BiologyPreprint
Dynamic modelling of EWS::FLI1 fluctuations reveals molecular determinants of phenotypic tumor plasticity and prognosis in Ewing sarcoma
Veveeyan SureshiD, Christoph HafemeisteriD, Andri KonstantinouiD, Sarah GrissenbergeriD, Caterina SturtzeliD, Florencia Cidre‐AranaziD, Andrea Wenninger-WeinzierliD, Martha Magdalena ZylkaiD, Karla C. S. QueiroziD, Dorota KurekiD, Ana Sastre UrgellésiD, Javier AlonsoiD, Martin DisteliD, Anna C. ObenaufiD, Thomas G. P. GrünewaldiD, Florian HalbritteriD, Heinrich KovariD, Valerie FockiD
Abstract
The mechanisms underlying tumor cell plasticity driving drug resistance and disease progression remain poorly understood. In Ewing sarcoma (EwS), variations in EWS::FLI1 (EF) activity have been associated with epithelial-mesenchymal plasticity (EMP). Using degron technology, we titrated endogenous EF in an EwS cell line and linked phenotypic states to distinct EF thresholds. Strikingly, modest EF depletion promoted a pro-metastatic phenotype, that diminished upon near-complete EF loss. Nascent RNA sequencing revealed distinct gene clusters with heterogenous response patterns to varying EF dosage. Target genes most sensitive to subtle EF depletion contained GGAA microsatellites in EF-bound enhancers. Furthermore, we identified Kruppel-like zinc-finger transcription factors associated with EF-repressed EMP genes. Transient EF depletion followed by rapid restoration to simulate oncoprotein fluctuations identified persistently dysregulated genes associated with poor prognosis. This study underscores the therapeutic challenge of insufficient EF inhibition and provides a foundation for exploiting oncoprotein dynamics to uncover therapeutic vulnerabilities in fusion-driven cancers. Beyond EwS, our results underscore the broader impact of oncoprotein dosage dynamics in cancers with otherwise quiet genomes. SIGNIFICANCEWe report EwS as a paradigm for the importance of oncogene fluctuations in tumor cell plasticity and disease progression. Effective therapeutic strategies must ensure complete EF depletion to prevent inadvertent metastasis.
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: experimental assay
- Citations
- 3
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Endogenous EWSR1-FLI1 degron alleles enable control of fusion oncoprotein expression in tumor cell lines and xenografts
James H. McGinnis, Alberto E. Bremauntz, … David G. McFadden·bioRxiv·Oct 27, 2024
- Single-cell RNA Profiling Identifies Diverse Cellular Responses to EWSR1-FLI1 Down-regulation in Ewing Sarcoma
R. Khoogar, E. Lawlor, … P. J. Houghton·bioRxiv·Aug 30, 2019
- ETS1, a target gene of the EWSR1::FLI1 fusion oncoprotein, regulates the expression of the focal adhesion protein TENSIN3
V. J. Ebegboni, T. L. Jones, … N. Caplen·bioRxiv·Dec 21, 2023
- Systems biology analysis identifies TCF7L1 as a key regulator of metastasis in Ewing sarcoma
F. Cidre-Aranaz, J. Li, … T. G. P. Gruenewald·bioRxiv·Feb 25, 2021
- Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1
Q. Deng, R. Natesan, … i. a. asangani·bioRxiv·Feb 22, 2021
- Transcriptional programs define intratumoral heterogeneity of Ewing sarcoma at single cell resolution
M.-M. Aynaud, O. Mirabeau, … A. Zinovyev·bioRxiv·Apr 30, 2019